Lansforsakringar Fondforvaltning’s Teva Pharmaceuticals TEVA Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.69M	Sell	256,489 -1,420	-0.6%	-$47.3K	0.04%	331
2026 Q1	$7.77M	Buy	257,909 +1,501	+0.6%	+$48.3K	0.04%	321
2025 Q4	$8M	Buy	256,408 +4,736	+2%	+$117K	0.04%	321
2025 Q3	$5.08M	Buy	251,672 +755	+0.3%	+$13.3K	0.03%	400
2025 Q2	$4.21M	Buy	250,917 +811	+0.3%	+$13.1K	0.02%	418
2025 Q1	$3.84M	Buy	250,106 +5,344	+2%	+$95.5K	0.02%	435
2024 Q4	$5.39M	Buy	+244,762	New	+$4.45M	0.03%	388

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Lansforsakringar Fondforvaltning's TEVA Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its Teva Pharmaceuticals (TEVA) stake by 0.55% in Q2 2026, selling an estimated $47.3K and leaving 256,489 shares worth $8.69M. The position accounts for 0.04% of the portfolio, ranked #331.

Lansforsakringar Fondforvaltning first reported a position in TEVA in Q4 2024 and has held it in 7 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Lansforsakringar Fondforvaltning held 256,489 shares of Teva Pharmaceuticals worth $8.69M as of Q2 2026.
Lansforsakringar Fondforvaltning sold 1,420 Teva Pharmaceuticals shares in Q2 2026, an estimated $47.3K.
Teva Pharmaceuticals made up 0.04% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #331 holding.
Lansforsakringar Fondforvaltning first reported a position in Teva Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.